Armen Shanafelt

Armen Shanafelt is a declared insider at 4 companies (board member); the most frequent names are Protagonist Therapeutics, Inc, Spyre Therapeutics, Inc. and Rein Therapeutics, Inc. In total, 11 filings cover trades dated from 16 August 2016 to 13 December 2021.

No open-market sale appears; the market trades are 6 purchases worth €13.3M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. In 2021 alone, the filings show 3 purchases and no sales.

Half of the purchases are above €1.8M and half below. Of 5 purchases, 5 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Ninety days after publication, 3 purchases show a median change of -51.8%, with the price up in 0% of them. Past outcomes like these are no guarantee of what comes next.

Most recently, on 13 December 2021, the filings show an open-market purchase worth €44k in Spyre Therapeutics, Inc. Most trades are made public on the day they happen. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.